KRAS and colonic neoplasm: Trametinib decreased ERK phosphorylation in K-Ras mutant colon cancer cells, while it also induced a strong expression of P-JAK2 and a moderate expression of P-JAK3, the upstream kinases that phosphorylate STAT3 (HCT116 cells as a representative, Figure 2C).